## Xiangyan Ruan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1330071/publications.pdf

Version: 2024-02-01

123	1,591	22	32
papers	citations	h-index	g-index
129	129	129	1423
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Dual Regulatory Role of MiR-181a in Breast Cancer. Cellular Physiology and Biochemistry, 2017, 44, 843-856.	1.1	82
2	The pharmacology of dienogest. Maturitas, 2012, 71, 337-344.	1.0	65
3	Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause, 2017, 24, 203-209.	0.8	50
4	Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric, 2012, 15, 467-472.	1.1	48
5	Possible role of PGRMC1 in breast cancer development. Climacteric, 2013, 16, 509-513.	1.1	47
6	Impact of smoking on estrogenic efficacy. Climacteric, 2015, 18, 38-46.	1.1	46
7	The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it. Menopause, 2010, 17, 566-570.	0.8	43
8	The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause, 2011, 18, 845-850.	0.8	42
9	The pharmacology of nomegestrol acetate. Maturitas, 2012, 71, 345-353.	1.0	40
10	Genomic and non-genomic actions of progestogens in the breast. Journal of Steroid Biochemistry and Molecular Biology, 2014, 142, 62-67.	1.2	33
11	Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological Endocrinology, 2018, 34, 413-417.	0.7	33
12	Study on Chronic Low-Grade Inflammation and Influential Factors of Polycystic Ovary Syndrome. Medical Principles and Practice, 2009, 18, 118-122.	1.1	32
13	Prevalence of climacteric symptoms comparing perimenopausal and postmenopausal Chinese women. Journal of Psychosomatic Obstetrics and Gynaecology, 2017, 38, 161-169.	1.1	31
14	Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment. Fertility and Sterility, 2018, 109, 720-727.	0.5	31
15	Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecological Endocrinology, 2012, 28, 863-866.	0.7	30
16	Overexpression of progesterone receptor membrane component 1. Menopause, 2013, 20, 504-510.	0.8	30
17	Systemic progesterone therapy—Oral, vaginal, injections and even transdermal?. Maturitas, 2014, 79, 248-255.	1.0	28
18	Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric, 2018, 21, 140-147.	1.1	28

#	Article	IF	Citations
19	Oxidative stress indicators in Chinese women with PCOS and correlation with features of metabolic syndrome and dependency on lipid patterns. Archives of Gynecology and Obstetrics, 2019, 300, 1413-1421.	0.8	28
20	Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecological Endocrinology, 2014, 30, 836-839.	0.7	26
21	May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?. Gynecological Endocrinology, 2016, 32, 58-60.	0.7	26
22	Benefit–risk profile of black cohosh (isopropanolic <i>Cimicifuga racemosa</i> extract) with and without St John's wort in breast cancer patients. Climacteric, 2019, 22, 339-347.	1.1	25
23	Prevalence of and risk factors for sexual dysfunction in young Chinese women according to the Female Sexual Function Index: an internet-based survey. European Journal of Contraception and Reproductive Health Care, 2016, 21, 259-263.	0.6	24
24	Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. European Journal of Contraception and Reproductive Health Care, 2017, 22, 183-190.	0.6	24
25	The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model. Maturitas, 2017, 102, 26-33.	1.0	24
26	Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics, 2018, 297, 1557-1563.	0.8	24
27	Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management?. Current Pharmaceutical Design, 2019, 24, 4685-4692.	0.9	23
28	Case report of the first successful cryopreserved ovarian tissue retransplantation in China. Climacteric, 2018, 21, 613-616.	1.1	22
29	Review & amp; meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms $\hat{a}\in$ an update on the evidence. Climacteric, 2021, 24, 109-119.	1.1	22
30	Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study. Maturitas, 2019, 123, 1-8.	1.0	21
31	Effect of laparoscopic endometrioma cystectomy on anti-MÃ $^1\!/\!4$ llerian hormone (AMH) levels. Gynecological Endocrinology, 2019, 35, 494-497.	0.7	20
32	Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecological Endocrinology, 2013, 29, 160-162.	0.7	19
33	Chinese Society of Gynecological Endocrinology affiliated to the International Society of Gynecological Endocrinology Guideline for Ovarian Tissue Cryopreservation and Transplantation. Gynecological Endocrinology, 2018, 34, 1005-1010.	0.7	19
34	Randomized study to prove the quality of human ovarian tissue cryopreservation by xenotransplantation into mice. Journal of Ovarian Research, 2019, 12, 46.	1.3	19
35	Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. Gynecological Endocrinology, 2015, 31, 548-551.	0.7	18
36	Ovarian tissue cryopreservation and transplantation prevents iatrogenic premature ovarian insufficiency: first 10 cases in China. Climacteric, 2020, 23, 574-580.	1.1	18

#	Article	IF	Citations
37	Identification of PGRMC1 as a Candidate Oncogene for Head and Neck Cancers and Its Involvement in Metabolic Activities. Frontiers in Bioengineering and Biotechnology, 2019, 7, 438.	2.0	18
38	Oral contraception for women of middle age. Maturitas, 2015, 82, 266-270.	1.0	17
39	Ovarian tissue cryopreservation for patients with premature ovary insufficiency caused by cancer treatment: optimal protocol. Climacteric, 2019, 22, 383-389.	1.1	17
40	<p>Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women</p> . Clinical Interventions in Aging, 2020, Volume 15, 2195-2208.	1.3	16
41	Oneâ€pot synthesis of highly fluorescent silicon nanoparticles for sensitive and selective detection of hemoglobin. Electrophoresis, 2019, 40, 2129-2134.	1.3	15
42	Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers. Menopause, 2020, 27, 183-193.	0.8	15
43	Anti-MÃ $^{1}\!/\!$ llerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecological Endocrinology, 2014, 30, 126-129.	0.7	14
44	Menopausal symptoms among Chinese peri- and postmenopausal women: a large prospective single-center cohort study. Gynecological Endocrinology, 2021, 37, 185-189.	0.7	14
45	Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth. Maturitas, 2018, 114, 60-66.	1.0	13
46	The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case–control studies. Archives of Gynecology and Obstetrics, 2015, 291, 1141-1146.	0.8	12
47	Oestetrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: Comparison of four oestrogens. European Journal of Contraception and Reproductive Health Care, 2015, 20, 29-35.	0.6	12
48	The pattern of lipids and lipoproteins during the menopausal transition in Chinese women. Climacteric, 2016, 19, 292-298.	1.1	12
49	Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes. Gynecological Endocrinology, 2016, 32, 151-156.	0.7	11
50	Early clinical features and risk factors for cesarean scar pregnancy: a retrospective case-control study. Gynecological Endocrinology, 2019, 35, 337-341.	0.7	11
51	Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. Gynecological Endocrinology, 2020, 36, 190-196.	0.7	11
52	Analysis of Fertility Preservation by Ovarian Tissue Cryopreservation in Pediatric Children in China. Frontiers in Endocrinology, $0,13,13$	1.5	11
53	Management strategy of infertility in polycystic ovary syndrome. Global Health Journal (Amsterdam,) Tj ETQq1 1	. 0.784314 1.9	f rgBT /Overlo
54	First live birth in China after cryopreserved ovarian tissue transplantation to prevent premature ovarian insufficiency. Climacteric, 2022, 25, 421-424.	1.1	10

#	Article	IF	CITATIONS
55	Benefits and risks during HRT: main safety issue breast cancer. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 105-116.	0.3	9
56	The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. Gynecological Endocrinology, 2017, 33, 332-335.	0.7	9
57	Membrane-initiated effects of Serelys (sup) $\hat{A}^{\otimes}$ (sup) on proliferation and apoptosis of human breast cancer cells. Gynecological Endocrinology, 2018, 34, 353-356.	0.7	9
58	PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol. Climacteric, 2019, 22, 483-488.	1.1	9
59	Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics. Maturitas, 2020, 140, 64-71.	1.0	9
60	First pregnancy in China after ovarian tissue transplantation to prevent premature ovarian insufficiency. Climacteric, 2021, 24, 624-628.	1.1	9
61	Chinese obstetrician-gynecologists still need more education in menopausal hormone therapy. Menopause, 2014, 21, 1170-1172.	0.8	8
62	PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study. Gynecological Endocrinology, 2020, 36, 1024-1027.	0.7	8
63	Abnormalities of early folliculogenesis and serum anti-Mýllerian hormone in chinese patients with polycystic ovary syndrome. Journal of Ovarian Research, 2021, 14, 36.	1.3	8
64	Breast cancer risk during hormone therapy: experimental versus clinical data. Minerva Endocrinologica, 2012, 37, 59-74.	1.7	7
65	Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters. Gynecological Endocrinology, 2017, 33, 694-697.	0.7	6
66	The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue. Hormone Molecular Biology and Clinical Investigation, 2019, 37, .	0.3	6
67	Importance of active and passive smoking as one of the risk factors for female sexual dysfunction in Chinese women. Gynecological Endocrinology, 2021, 37, 541-545.	0.7	6
68	MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR–PI3K/Akt/mTOR signaling pathway. Translational Oncology, 2021, 14, 101068.	1.7	6
69	Long-time low-temperature transportation of human ovarian tissue before cryopreservation. Reproductive BioMedicine Online, 2021, 43, 172-183.	1.1	6
70	E2 + norethisterone promotes the PI3K–AKT pathway via PGRMC1 to induce breast cancer cell proliferation. Climacteric, 2022, 25, 467-475.	1.1	6
71	Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report. Journal of Ovarian Research, 2021, 14, 176.	1.3	6
72	Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study. Gynecological Endocrinology, 2017, 33, 462-466.	0.7	5

#	Article	IF	Citations
73	Acupuncture for menopausal symptoms in Chinese women: a systematic review. Climacteric, 2021, 24, 68-73.	1.1	5
74	Sexual dysfunction in Chinese women at different reproductive stages and the positive effect of hormone replacement therapy in the early postmenopause. European Journal of Contraception and Reproductive Health Care, 2021, 26, 246-254.	0.6	5
75	Genitourinary syndrome of menopause in Chinese perimenopausal and postmenopausal women. Climacteric, 2021, 24, 297-304.	1.1	5
76	Ovarian tissue cryopreservation: prospective randomized study on thawed ovarian tissue viability to estimate the maximum possible delivery time of tissue samples. Gynecological Endocrinology, 2019, 35, 591-594.	0.7	4
77	How much total ovarian tissue can be removed without compromising ovarian function? An animal study. Gynecological Endocrinology, 2021, 37, 240-245.	0.7	4
78	Lumbar bone mineral density measured by quantitative computed tomography (QCT): association with abdominal adipose tissue in different menopausal periods of Chinese women. Gynecological Endocrinology, 2021, 37, 264-268.	0.7	4
79	Sexual Function in Chinese Women with Polycystic Ovary Syndrome and Correlation with Clinical and Biochemical Characteristics. Reproductive Sciences, 2021, 28, 3181-3192.	1.1	4
80	Comprehensive Analysis of the Implication of PGRMC1 in Triple-Negative Breast Cancer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 714030.	2.0	4
81	Primary choice of estrogen and progestogen as components for HRT: a clinical pharmacological view. Climacteric, 2022, 25, 443-452.	1.1	4
82	Progesterone Receptor Membrane Component-1 May Promote Survival of Human Brain Microvascular Endothelial Cells in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 153331752211097.	0.9	4
83	Dependency of cardiovascular risk on reproductive stages and on age among middle-aged Chinese women. Climacteric, 2017, 20, 484-490.	1.1	3
84	Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy?. Climacteric, 2019, 22, 535-537.	1.1	3
85	Intrauterine contraception and menstrual bleeding. Global Health Journal (Amsterdam, Netherlands), 2021, 5, 66-69.	1.9	3
86	Prevention and treatment of iatrogenic premature ovarian insufficiency: interpretation of the first Chinese guideline on ovarian tissue cryopreservation and transplantation. Global Health Journal (Amsterdam, Netherlands), 2021, 5, 70-73.	1.9	3
87	Efficacy and safety of Zi Gui Nv Zhen $\hat{A}^{\odot}$ capsules used in TCM for fertility preservation in patients with diminished ovarian reserve. Gynecological Endocrinology, 2021, , 1-5.	0.7	3
88	Expression of PGRMC1 in paraffin-embedded tissues of breast cancer. International Journal of Clinical and Experimental Pathology, 2017, 10, 9639-9643.	0.5	3
89	Is anti-Mullerian hormone a useful biomarker in the diagnosis of polycystic ovary syndrome in Chinese adolescents?. Gynecological Endocrinology, 2022, , 1-5.	0.7	3
90	Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat. Gynecological Endocrinology, 0, , 1-5.	0.7	3

#	Article	IF	Citations
91	The first family group of $\hat{l}\pm 1$ -AT-P in the world with repeated hematomas: 10-year follow-up. Climacteric, 2019, 22, 527-530.	1.1	2
92	Simultaneous detection of CA15-3 and PGRMC1 on a microfluidic chip for early diagnosis of breast cancer. Journal of Liquid Chromatography and Related Technologies, 2021, 44, 519-528.	0.5	2
93	Optimizing menopausal hormone therapy: for treatment and prevention, menstrual regulation, and reduction of possible risks. Global Health Journal (Amsterdam, Netherlands), 2022, , .	1.9	2
94	Membrane-bound progesterone receptor1 (PGRMC1) can mediate breast cancer proliferation significantly stronger with E2/norethisterone compared to E2/progesterone – A xenograft model. Maturitas, 2017, 100, 172.	1.0	1
95	Can blood concentrations of progesterone receptor membrane component-1 (PGRMC1) predict the risk of patients with breast cancer?. Maturitas, 2019, 124, 183.	1.0	1
96	The progress and prospect of assessment measures of uterine cavity function for infertility patients. Global Health Journal (Amsterdam, Netherlands), 2021, 5, 79-82.	1.9	1
97	MicroRNA-181a Suppresses Progestin-Stimulated Breast Cancer Cell Growth. Journal of Cancer Treatment & Diagnosis, 2018, 2, 1-5.	0.9	1
98	Advanced therapy of overweight or obese polycystic ovary syndrome: a prospective study. Global Health Journal (Amsterdam, Netherlands), 2022, , .	1.9	1
99	Effect of orlistat during individualized comprehensive life-style intervention on visceral fat in overweight or obese PCOS patients. Gynecological Endocrinology, 0, , 1-5.	0.7	1
100	Increased expression of PGRMC1 is associated with poor prognosis of breast cancer patients. Maturitas, 2017, 100, 172.	1.0	0
101	WHO claims "Estrogens are carcinogenic―– Is this true?. Maturitas, 2017, 100, 104.	1.0	0
102	Estradiol-based contraceptives for perimenopausal patients?. Maturitas, 2017, 100, 111-112.	1.0	0
103	Progestogens and breast cancer – Importance of membrane receptors. Maturitas, 2017, 100, 105-106.	1.0	O
104	Membrane-bound progesterone receptor to predict the prognosis of breast cancer. Maturitas, 2017, 100, 106.	1.0	0
105	Menopausal symptoms – Comparing East and West. Maturitas, 2017, 100, 111.	1.0	O
106	Vascular Effects of Progestogens. ISGE Series, 2019, , 197-207.	0.2	0
107	Growth of PGRMC1-transfected tumors is increased with norethisterone, but not with progesterone or dydrogesterone, and is correlated to PGRMC1 blood concentrations: a xenograft study. Maturitas, 2019, 124, 144.	1.0	0
108	Prevalence of different phenotypes and their lipid pattern assessed in Chinese women with polycystic ovary syndrome. Maturitas, 2019, 124, 181.	1.0	0

#	Article	IF	CITATIONS
109	PGRMC1 increased estradiol triggered tumor growth of nude mice: a xenograft animal study. Maturitas, 2019, 124, 182.	1.0	0
110	Sexual dysfunction and urogenital complaints comparing perimenopausal and postmenopausal women based on a cross-sectional survey in China. Maturitas, 2019, 124, 181.	1.0	0
111	PGRMC1 can increase progestogen induced proliferation of breast cancer cells: comparing sequential vs. continuous combination with estradiol. Maturitas, 2019, 124, 182.	1.0	0
112	Diseases of the patients getting cryopreserved ovarian tissue: comparing a centralized fertility protection center in Europe with the first ovarian tissue cryobank in China. Maturitas, 2019, 124, 183.	1.0	0
113	The proliferative effect of progesterone receptor membrane component 1 (PGRMC1) may be related to interaction with estrogen receptor $\hat{l}_{\pm}$ - a xenograft animal study. Maturitas, 2019, 124, 179.	1.0	0
114	Norethisterone in contrast to progesterone dose-dependently increases breast cancer cell proliferation by increasing the expression of PGRMC1. Maturitas, 2019, 124, 179.	1.0	0
115	PGRMC1 can increase progestogen induced proliferation of breast cancer cells: different effects of six synthetic progestogens and progesterone. Maturitas, 2019, 124, 180.	1.0	0
116	Etiology of premature ovarian insufficiency (POI) and risk factors assessed in Chinese patients. Maturitas, 2019, 124, 185.	1.0	0
117	MicroRNA-181a suppresses progestin-promoted oncogenic transformation of breast epithelial cells through interfering PGRMC1 signalling pathway. Maturitas, 2019, 124, 143-144.	1.0	0
118	A prospective randomized comparative study of comprehensive intervention using Orlistat to reduce visceral fat of overweight or obese PCOS patients. Maturitas, 2019, 124, 180.	1.0	0
119	Expression of ER, PR, HER-2 and Ki67 before and after neoadjuvant chemotherapy (NAC) and the relation between their expression and the curative effects of NAC in breast cancer patients. Maturitas, 2019, 124, 184-185.	1.0	0
120	Oxidative stress parametersin women with polycystic ovary syndrome with and without metabolic syndromecomparing with healthy women. Maturitas, 2019, 124, 184.	1.0	0
121	Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China. Climacteric, 2021, , 1-7.	1.1	0
122	Management of PCOS Women Preparing Pregnancy. ISGE Series, 2021, , 135-147.	0.2	0
123	Infertile women with endometriosis possess differences in cytokine levels in various tissues. Gynecological Endocrinology, 2022, , 1-5.	0.7	0